Autoimmune encephalitis in a woman with lung adenocarcinoma undergoing treatment with an immune checkpoint inhibitor (Pembrolizumab). What was the trigger: The neoplasm or the treatment?

Current Problems in Cancer: Case Reports · Published 2026-04-02 · DOI 10.1016/j.cpccr.2026.100418

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.cpccr.2026.100418

Abstract

Autoimmune encephalitis is a condition where patients typically present with short-term memory deficits, psychiatric symptoms, and seizures, all with rapid progression. Recently, cases of limbic encephalitis associated with the use of new antibodies for cancer treatment have been reported, such as the monoclonal antibodies (mAb) IgG4 nivolumab and pembrolizumab, which block the binding of PD-1 to PD-L1 and PD-L2 ligands in the tumor microenvironment. We present the first case of limbic encephalitis related to the use of Pembrolizumab in Mexico.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Related articles